title: [Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment].
abstract: OBJECTIVE
  In Spain, use of the Framingham-REGICOR (Registre Gironí del Cor) and SCORE (Systematic Coronary Risk Evaluation) risk charts is recommended for stratifying cardiovascular disease risk. The aims of the present study were to evaluate the degree of agreement between these charts when used to evaluate cardiovascular disease risk in nondiabetic individuals aged 40-65 years and to estimate the percentage of patients recommended for hypolipidemic or antihypertensive treatment.
  
  
  METHODS
  The study included 608 nondiabetic patients aged between 40-65 years (mean 52.8 years, 56.7% female) with no evidence of cardiovascular disease who were attending a primary healthcare center between 1990-1994. REGICOR and SCORE equations were used to calculate 10-year cardiovascular disease risks. Patients were classified as high-risk if their risk was > or =10% with REGICOR or > or =5% with SCORE.
  
  
  RESULTS
  Some 7.9% of the population was classified as high-risk with REGICOR and 9.2%, with SCORE (P=.41). Only 2.6% and 2.9% (P=.81) of women were classified as high-risk, compared with 14.8% and 17.5% of men, with REGICOR and SCORE, respectively (P=.40). The kappa coefficient was 0.45. According to European professional society guidelines, 23.8% of patients classified by SCORE and 23.0% classified by REGICOR (P=.73) would be recommended hypolipidemic treatment, while 31.2% and 31.7% (P=.85), respectively, would be recommended antihypertensive treatment.
  
  
  CONCLUSIONS
  There was moderately good agreement between REGICOR and SCORE charts when used to evaluate nondiabetic individuals aged 40-65 years. They identified similar percentages of patients who would be recommended for hypolipidemic or antihypertensive treatment.
authors.affiliation: Unidad Docente de Medicina Familiar y Comunitaria, Centro de Salud Universitario La Paz, Servicio Extremeño de Salud, Badajoz, Spain. fbuitragor@meditex.es
authors.forename: Francisco
authors.initials: F
authors.lastname: Buitrago
authors.forename: Lourdes
authors.initials: L
authors.lastname: Cañón-Barroso
authors.forename: Natalio
authors.initials: N
authors.lastname: Díaz-Herrera
authors.forename: Eloísa
authors.initials: E
authors.lastname: Cruces-Muro
authors.forename: Miguel
authors.initials: M
authors.lastname: Escobar-Fernández
authors.forename: José M
authors.initials: JM
authors.lastname: Serrano-Arias
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001795:Blood Pressure Determination; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003430:Cross-Sectional Studies; D005260:Female; D006304:Health Status; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012737:Sex Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents; D014280:Triglycerides